罗沙司他在肾性贫血患者中的应用及对机体炎性介质和心肌酶谱的影响  

The Application of Roxadustat in Patients with Renal Anemia and Its Effects on Inflammatory Mediators and Myocardial Enzymes

作　　者：田丽会 刘飞[1] 郭红萍[1] 陈伟 TIAN Lihui;LIU Fei;GUO Hongping(Linfen People's Hospital,Shanxi Linfen 041000,China)

机构地区：[1]山西省临汾市人民医院肾脏内科,山西临汾041000 [2]山西省太原市第四人民医院肾脏内科,山西太原030000

出　　处：《河北医学》2023年第7期1213-1217,共5页Hebei Medicine

基　　金：山西省自然科学基金,(编号:202001D121314)。

摘　　要：目的:探讨罗沙司他在肾性贫血患者中的应用及对机体炎性介质和心肌酶谱的影响。方法:根据随机数字分组原则,将2020年10月至2021年12月收治的90例肾性贫血患者随机分为空白组(n=45)与研究组(n=45)。空白组接受肾性贫血患者常规治疗,研究组采用罗沙司他联合治疗,比较治疗疗效,观察治疗前后铁代谢指标[转铁蛋白(TRF)、转铁蛋白饱和度(TSAT)、血清铁蛋白(SF)和铁调素(Hepc)]、炎性介质[白细胞介素6(IL-6)和C反应蛋白(CRP)]、心肌酶谱指标[磷酸肌酸激酶(CK)、磷酸肌酸激酶同工酶(CK-MB)、乳酸脱氢酶(LDH)]和不良反应发生情况。结果:研究组治疗效果、SF、TRF及TSAT水平均较空白组高(P<0.05)。研究组Hepc、IL-6、CRP、CK、CK-MB及LDH水平低于空白组(P<0.05)。两组患者各项不良反应发生情况比较无统计学差异(P>0.05)。结论:罗沙司他对肾性贫血患者疗效较好,有效改善铁代谢水平和炎症状态,同时降低心肌酶谱指标,但对治疗期间不良反应发生情况影响较小。Objective:To investigate the effect of Roxadustat on inflammatory mediators and myocardial enzymes in patients with renal anemia.Methods:According to the principle of random number grouping,90 patients with renal anemia admitted from October 2020 to December 2021 were divided into an observation group and a control group,with 45 patients in each group..The patients in the control group were treated with routine anti anemia therapy,while the patients in the observation group were treated with Roxadustat on the basis of the treatment in the control group,and the therapeutic effects,iron metabolism indicators[serum ferritin(SF),transferrin(TRF),transferrin saturation(TSAT),and ferrimodulin(Hepc)],inflammatory mediators[interleukin-6(IL-6)and C-reactive protein(CRP)]Myocardial zymogram indicators[phosphocreatine kinase(CK),phosphocreatine kinase isoenzyme(CK-MB),lactate dehydrogenase(LDH)]and adverse reactions were compared.Results:The therapeutic effect,SF,TRF and TSAT levels in the observation group were higher than those in the control group(P<0.05).After treatment,the levels of Hepc,IL-6,CRP,CK,CK-MB and LDH in the observation group were lower than those in the control group(P<0.05).There was no statistical difference between the two groups in the incidence of adverse reactions(P>0.05).Conclusion:Rosalrestat has a good effect on patients with renal anemia.It can effectively improve the level of iron metabolism and inflammatory state,and reduce the indexes of myocardial zymogram,but it has little effect on the occurrence of adverse reactions during treatment.

关 键 词：罗沙司他 肾性贫血 炎性介质 心肌酶谱 

分 类 号：R692.5[医药卫生—泌尿科学] R556[医药卫生—外科学]